Adjuvant immune checkpoint blockade revisited
The Lancet Oncology, vol. 24, pp. 717–719
Authors 7
-
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani corresponding Aachen Department of Medical Oncology
Leiden University · Leiden University Medical Center · Centraal Ziekenfonds (Netherlands)
Affiliation as printed
Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, Netherlands; Medical Department, CZ Health Insurance, Tilburg, Netherlands. Electronic address: sahar.van.waalwijk@cz.nl
Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, Netherlands
Medical Department, CZ Health Insurance, Tilburg, Netherlands
-
Affiliation as printed
Department of Health Policy, Zorgverzekeraars Nederland, Zeist, Netherlands
-
Centraal Ziekenfonds (Netherlands)
Affiliation as printed
Medical Department, CZ Health Insurance, Tilburg, Netherlands
-
Affiliation as printed
Medical Department, ONVZ Health Insurance, Houten, Netherlands
-
Affiliation as printed
Scientific Advisory Board, National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands
-
Leiden University · Leiden University Medical Center · The Netherlands Cancer Institute
Affiliation as printed
Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, Netherlands; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, Netherlands
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
-
Leiden University · Leiden University Medical Center
Affiliation as printed
Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA, Leiden, Netherlands
Cited by 8 stored of 8
8 results
No patents citing this paper on Lens.org (checked 2026-10-11).
References 10
-
W6838399393details pending0citations
10 results